知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.015 秒)

    Therapeutic fragments of von Willebrand factor
    1.
    发明授权
    Therapeutic fragments of von Willebrand factor 失效
    von Willebrand因子的治疗片段

    公开(公告)号：US5847086A

    公开(公告)日：1998-12-08

    申请号：US487445

    申请日：1995-06-07

    申请人： David L. Farb ,  Michael E. Hrinda ,  Ted C. K. Lee ,  Christopher P. Prior ,  David Weber

    发明人： David L. Farb ,  Michael E. Hrinda ,  Ted C. K. Lee ,  Christopher P. Prior ,  David Weber

    IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K38/36 ,  A61P7/02 ,  A61P9/00 ,  A61P43/00 ,  C07K1/22 ,  C07K14/745 ,  C07K14/755 ,  A61K35/14

    CPC分类号： C07K14/755 ,  A61K38/00

    摘要： Processes for preparing aqueous solutions of cysteine-altered von Willebrand Factor fragment which are substantially free of aggregate and capable of therapeutic use for treating thrombosis are provided. The claimed process comprises providing an aqueous solution of vWF fragment and denaturant and containing undesired contaminants, said solution having an acidic pH; separating said contaminants from said solution by contacting said solution with an affinity chromatography medium to which said vWF fragments adhere; eluting said vWF fragment from said affinity chromatography medium in the presence of the denaturant; and separating the eluted fragment from said denaturant while maintaining the aqueous solution of the fragment at a pH of about 2.5 to less than about 5.5 to increase monomerization of, and decrease aggregation of, said fragment, thereby forming an aqueous solution of vWF fragment which is substantially free of aggregate.

    摘要翻译： 提供了制备基本上不含聚集体并能治疗用于治疗血栓形成的半胱氨酸改变的血管性血友病因子片段的水溶液的方法。 所要求的方法包括提供vWF片段和变性剂的水溶液并含有不期望的污染物，所述溶液具有酸性pH; 通过使所述溶液与所述vWF碎片粘附到的亲和层析介质接触来分离所述污染物; 在变性剂存在下，从所述亲和层析介质中洗脱所述vWF片段; 并将洗脱的片段与所述变性剂分离，同时将片段的水溶液保持在约2.5至小于约5.5的pH，以增加所述片段的单体化和降低聚集，由此形成vWF片段的水溶液，其为 基本上不含聚集体。

    Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
    3.
    发明授权
    Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants 失效
    在病毒和细菌污染物的热失活期间稳定生物和药物产品

    公开(公告)号：US4876241A

    公开(公告)日：1989-10-24

    申请号：US195318

    申请日：1988-05-18

    申请人： Fred Feldman ,  Mark S. Klekamp ,  Michael E. Hrinda ,  Arthur B. Shaw ,  Sudhish Chandra

    发明人： Fred Feldman ,  Mark S. Klekamp ,  Michael E. Hrinda ,  Arthur B. Shaw ,  Sudhish Chandra

    IPC分类号： A61L2/00

    CPC分类号： A61L2/0023 ,  A61L2/0005

    摘要： A method of inactivating pathogens in proteinaceous biological and pharmaceutical products which comprises: mixing the product in an aqueous solution with one or more primary stabilizers selected from the group consisting of sugars and sugar alcohols and one or more secondary stabilizers selected from the group consisting of sodium acetate, potassium acetate, lithium acetate, magnesium acetate, ammonium acetate, barium acetate, sodium sulfate, ammonium sulfate, lithium sulfate, potassium sulfate and magnesium sulfate; and subjecting said aqueous solution to a pathogen inactivating process.

    摘要翻译： 一种灭活蛋白质生物和药物产品中的病原体的方法，其包括：将产物在水溶液中与一种或多种主要稳定剂混合，所述主要稳定剂选自糖和糖醇，以及一种或多种二级稳定剂，其选自钠 乙酸钾，乙酸钾，乙酸锂，乙酸镁，乙酸铵，乙酸钡，硫酸钠，硫酸铵，硫酸锂，硫酸钾和硫酸镁; 并使所述水溶液进行病原体灭活过程。

    Methods for purification of recombinantly produced proteins
    5.
    发明授权
    Methods for purification of recombinantly produced proteins 失效
    纯化重组产生的蛋白质的方法

    公开(公告)号：US5530100A

    公开(公告)日：1996-06-25

    申请号：US519709

    申请日：1990-05-07

    申请人： Thomas L. J. Darling ,  Lida Y. Akhnana ,  Jonathan J. Mitschelen ,  Michael E. Hrinda

    发明人： Thomas L. J. Darling ,  Lida Y. Akhnana ,  Jonathan J. Mitschelen ,  Michael E. Hrinda

    IPC分类号： C07K14/755 ,  C07K3/08 ,  C07K3/12 ,  C07K3/20 ,  C07K15/06

    CPC分类号： C07K14/755

    摘要： Recovery of the 52/48 kDa tryptic fragment of vWF or peptide subfragments thereof produced in the form of inclusion bodies from recombinant host cells is carried out by providing a washed recombinant host cell suspension, adding a detergent and subjecting the cells to mechanical disruption. A second detergent is added, followed by another mechanical disruption and centrifugation to a pellet. The pellet is resuspended in a buffer and subjected to another mechanical disruption. Inclusion bodies are washed, resuspended and then recovered. In addition, endotoxins and DNA are removed from inclusion bodies containing the 52/48 kDa tryptic fragment of vWF or peptide subfragments thereof by mechanically disrupting the inclusion bodies in an aqueous buffer containing a detergent. A washed pellet is formed from these mechanically disrupted inclusion bodies and dissolved in a denaturant. Alkylation is then performed and the suspension is subjected to column chromatography, where the alkylated fragment or subfragment is recovered by elution.

    摘要翻译： 通过提供洗涤的重组宿主细胞悬浮液，加入洗涤剂并使细胞经受机械破坏来进行以来自重组宿主细胞的包涵体形式产生的vWF或其肽亚片段的52/48 kDa胰蛋白酶片段的回收。 加入第二种洗涤剂，然后再进行机械破碎并离心至沉淀。 将沉淀物重新悬浮在缓冲液中并进行另一种机械破坏。 将包涵体洗涤，重悬，然后回收。 此外，通过在含有洗涤剂的水性缓冲液中机械破坏包涵体，从含有vWF的52/48 kDa胰蛋白酶片段或其肽亚片段的包含体中除去内毒素和DNA。 由这些机械破碎的包涵体形成洗涤的颗粒并溶解在变性剂中。 然后进行烷基化，并将悬浮液进行柱色谱，其中通过洗脱回收烷基化的片段或亚片段。

    Therapeutic fragments of von Willebrand factor
    9.
    发明授权
    Therapeutic fragments of von Willebrand factor 失效
    von Willebrand因子的治疗片段

    公开(公告)号：US5539086A

    公开(公告)日：1996-07-23

    申请号：US198849

    申请日：1994-02-18

    申请人： David L. Farb ,  Michael E. Hrinda ,  Ted C. K. Lee ,  Christopher P. Prior

    发明人： David L. Farb ,  Michael E. Hrinda ,  Ted C. K. Lee ,  Christopher P. Prior

    IPC分类号： A61K38/00 ,  C07K1/113 ,  C07K14/755 ,  A61K38/37 ,  C07K1/14 ,  C07K14/745

    CPC分类号： C07K1/1136 ,  C07K14/755 ,  A61K38/00

    摘要： An aqueous solution of cysteine-altered von Willebrand Factor fragment which is substantially free of aggregate and capable of therapeutic use for treating thrombosis and a process for preparing such a solution comprising:(A) providing an aqueous solution of the fragment and denaturant;(B) purifying the solution of fragment and denaturant under conditions which promote conversion of aggregated forms of the fragment to the dimeric and/or monomeric forms thereof to provide purified fragment;(C) separating the dissolved, purified fragment from the denaturant while maintaining the aqueous solution of the fragment at a pH of about 2.5 to less than about 5.5 to increase monomerization of, and decrease aggregation of, said purified fragment, thereby forming an aqueous solution of fragment which is substantially free of aggregate.

    摘要翻译： 基本上不含聚集体并能治疗用于治疗血栓形成的半胱氨酸改变的血管性血友病因子片段的水溶液和制备这种溶液的方法，包括：（A）提供片段和变性剂的水溶液; （B）在促进片段的聚集形式转化为其二聚体和/或单体形式的条件下纯化片段和变性剂的溶液以提供纯化的片段; （C）将溶解的纯化的片段与变性剂分离，同时将片段的水溶液保持在约2.5至小于约5.5的pH下，以增加所述纯化片段的单体化并减少聚集，由此形成水溶液 基本上不含聚集体的片段。